home / stock / vtyx / vtyx quote
Last: | $4.04 |
---|---|
Change Percent: | -9.82% |
Open: | $4.84 |
Close: | $4.48 |
High: | $5.01 |
Low: | $3.8409 |
Volume: | 623,549 |
Last Trade Date Time: | 05/10/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.04 | $4.84 | $4.48 | $5.01 | $3.8409 | 623,549 | 05-10-2024 |
$4.48 | $4.5 | $4.48 | $4.63 | $4.38 | 555,102 | 05-09-2024 |
$4.44 | $4.51 | $4.44 | $4.62 | $4.4 | 377,701 | 05-08-2024 |
$4.605 | $4.74 | $4.605 | $4.87 | $4.57 | 342,916 | 05-07-2024 |
$4.71 | $4.9 | $4.71 | $4.995 | $4.6197 | 433,687 | 05-06-2024 |
$4.85 | $5.05 | $4.85 | $5.24 | $4.85 | 853,274 | 05-03-2024 |
$4.91 | $4.76 | $4.91 | $5.17 | $4.5638 | 1,909,345 | 05-02-2024 |
$4.68 | $3.78 | $4.68 | $4.9125 | $3.7 | 2,269,491 | 05-01-2024 |
$3.74 | $3.8 | $3.74 | $3.96 | $3.7 | 2,856,835 | 04-30-2024 |
$3.835 | $3.94 | $3.835 | $4.045 | $3.82 | 947,340 | 04-29-2024 |
$3.93 | $4.04 | $3.93 | $4.08 | $3.925 | 529,730 | 04-26-2024 |
$4.06 | $4.15 | $4.06 | $4.15 | $3.94 | 586,706 | 04-25-2024 |
$4.24 | $4.32 | $4.24 | $4.45 | $4.22 | 375,984 | 04-24-2024 |
$4.35 | $4.34 | $4.35 | $4.42 | $4.26 | 444,784 | 04-23-2024 |
$4.3 | $4.5 | $4.3 | $4.54 | $4.23 | 1,100,280 | 04-22-2024 |
$4.47 | $4.33 | $4.47 | $4.63 | $4.26 | 906,049 | 04-19-2024 |
$4.35 | $4.37 | $4.35 | $4.48 | $4.235 | 849,902 | 04-18-2024 |
$4.38 | $4.76 | $4.38 | $4.7683 | $4.36 | 780,158 | 04-17-2024 |
$4.76 | $4.62 | $4.76 | $4.82 | $4.55 | 661,262 | 04-16-2024 |
$4.67 | $4.64 | $4.67 | $4.83 | $4.595 | 628,944 | 04-15-2024 |
News, Short Squeeze, Breakout and More Instantly...
Ventyx Biosciences Inc. Company Name:
VTYX Stock Symbol:
NASDAQ Market:
Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson’s disease and in participants with obesity with certain additional cardiovascular risk factors Cash, cash equivalents and marketable securities of $302.6 million as ...
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focus...
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...